Castle Biosciences Named 3rd Best Places to Work for 2023 in Healthcare – Sep 19, 2023 at 07:02 AM EDT
Castle Biosciences, Inc. announced (Nasdaq: CSTL), a company that improves health through innovative tests that guide patient care, today announced that it has received a national industry award for Best Workplaces, ranking third among the 84 best workplaces in the healthcare industry. Castle received several additional Top Workplace awards this year, including Top Workplaces USA and Arizona Top Workplace awards, both for the second year in a row, as well as five Cultural Excellence Awards for Innovation, Work-Life Flexibility, Compensation and Benefits, and Leadership and Purpose. & Valuable.
“Being named a Top Workplace in the Healthcare Industry and ranked top nationally is a humbling accomplishment of which we are extremely proud,” said Derek Metzold, President and CEO of Castle Biosciences. “People come first at Castle, and our unique culture reflects that mindset. We attribute this award and our continued success to our dedicated employees, who are committed to helping us empower doctors and patients with personalized information that can help make important health care decisions.”
“Receiving a Best Places to Work award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, CEO of Energage. “This is something to be proud of. In today’s market, leaders must ensure they allow employees to have a voice and be heard. This is critical. The best workplaces do this, and it pays off.”
See the 2023 Best Places to Work in Healthcare winners.
About the citadel of biological sciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The company aims to transform disease management by keeping people first: patients, doctors, employees and investors.
Castle’s current portfolio consists of tests for melanoma, uveal melanoma, Barrett’s esophagus, and mental health conditions. In addition, the Company has active research and development programs for tests for other diseases with high clinical need, including a test in development to predict systemic therapeutic response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. To learn more, please visitAnd contact us on , , And .
DecisionDx-Skin Cancer, DecisionDx-CMsequenceDecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMsequenceTissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
Making the world a better place by working together.™
Energage is a company that aims to help organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Based on 16 years of cultural research and the results of 27 million employees surveyed across more than 70,000 organizations, Energage offers the most accurate competitive benchmark available. With access to a unique set of patented analytical tools and expert guidance, Energage customers lead the competition with an engaged workforce and the opportunity to gain recognition for their cultural approach that puts people first. For more information or to nominate your organization, visitor
(tags for translation) Markets